Current reviews

TACT is pleased to announce the following four applications that will be reviewed at the TACT meeting scheduled for 28 – 29 April, Arlington, VA, USA:

1. Fred Marin, PhD, GMP-Orphan SAS, France: Satisma: New drug formulation development program of sodium phenylbutyrate in SMA patients.
2. Urs Ruegg, PhD, University of Geneva, Geneva: Proposal for clinical investigation of tamoxifen in DMD boys based on results in dystrophic mice.
3. Joel Braunstein, MD, FACC, MBA, Tivorsan Pharmaceuticals, USA: Recombinant Biglycan for Treatment of Duchenne and Becker Muscular Dystrophy.
4. Paolo Bettica, MD, PhD, Italfarmaco. Italy: A two parts study to assess safety and tolerability, pharmacokinetics, effects on histology and on different clinical parameters of Givinostat in ambulant children with Duchenne Muscular Dystrophy.

According to the process TACT will generate a detailed report with program development recommendations to the applicant within 6 weeks following the meeting.  A non‐confidential report summary, developed in collaboration with the applicant, will be available via the TREAT‐NMD website within 8 weeks following the meeting (www.treat-nmd.eu/tact).

Dates for the subsequent TACT meeting have been confirmed as 27-28 October 2012 in Prague and individuals interested in potentially submitting an application should send an expression of interest to the TACT secretariat (Emma.Heslop@treat-nmd.eu) as soon as possible, and before the 27th July 2012.